#South Korea #Seoul #Biohaven #SK Biopharmaceuticals #Opakalim

SK Biopharmaceuticals Expands Its Portfolio with Opakalim In-Licensing

In a significant stride toward expanding its product offerings, SK Biopharmaceuticals announced at a recent press conference the in-licensing of Opakalim, an innovative antiseizure medication aimed at treating epilepsy. This strategic move signifies a pivotal transition for SK Biopharmaceuticals from a single-product company to a multi-product pharmaceutical entity capable of introducing advanced therapies directly into the U.S. market.

Overview of the Agreement

On August 26, 2026, SK Biopharmaceuticals finalized an agreement with Biohaven Ltd. to obtain the licensing rights for Opakalim, a selective Kv7 potassium channel activator with promising clinical efficacy. The arrangement potentially entails upfront payments and milestone payments amounting to up to $795 million. This includes $400 million in initial cash disbursement, further payments contingent upon development and regulatory milestones, alongside tiered royalties based on U.S. and international sales.

This agreement positions SK Biopharmaceuticals uniquely within the South Korean market, allowing it to directly market multiple innovative medicines globally, an unprecedented feat in the region's pharmaceutical landscape.

Clinical Potential of Opakalim

Opakalim is recognized for its potential in treating partial-onset seizures (POS) in adults. Early clinical studies conducted prior have indicated a favorable safety and tolerability profile compared to existing therapies. As the drug proceeds through Phase 2/3 of clinical testing, top-line data from the RISE 3 trial are anticipated by year-end, with a potential U.S. market launch projected as early as 2029 if regulatory hurdles are cleared.

SK Biopharmaceuticals expressed confidence in Opakalim's capability to fulfill a critical therapeutic niche for epilepsy patients. Their leadership highlighted an extensive evaluation process affirming the medication's strong likelihood of success and its distinctive benefits, particularly concerning tolerability.

Competitive Advantage

The launch of Opakalim is perceived not only as a new business venture but also as a strategic effort to bolster SK Biopharmaceuticals' foothold in the epilepsy treatment market. The company’s existing product, Cenobamate (XCOPRI®), has already gained recognition as one of the top new drugs within the U.S. epilepsy sector, further solidifying their market presence.

With both Cenobamate and Opakalim, SK Biopharmaceuticals aims to broaden the treatment landscape for epilepsy, offering additional alternatives that could translate into better outcomes for patients struggling with this condition. The company has put forth comprehensive efforts to establish a dedicated U.S. commercial organization with specialized teams focusing on neurology and epilepsy, thus enhancing their market access.

Insights from Company Leadership

Donghoon Lee, CEO of SK Biopharmaceuticals, described the in-licensing of Opakalim as a major strategic milestone. He highlighted the transition into a multi-product company as crucial for the future of SK Biopharmaceuticals, aiming to elevate the company’s reputation and operational capacity within the biopharmaceutical industry.

Furthermore, Vlad Coric, CEO of Biohaven, remarked on the unique features of Opakalim, emphasizing its low risk of side effects associated with CNS medications. This partnership is set to propel both companies forward in their quest for impactful solutions in epilepsy treatment.

Future Outlook

This licensing agreement marks a new chapter for SK Biopharmaceuticals as it vies for greater recognition and market share in the global pharmaceutical arena. As the company works through the phases of clinical development, it remains pivotal to monitor how Opakalim performs against existing and emerging competitors in the epilepsy treatment market.

In addition to Opakalim, SK Biopharmaceuticals is actively seeking to expand its global presence. Recent initiatives include launching Cenobamate in markets beyond the U.S., including China and several Latin American countries. The company is optimistic about its growth trajectory, continuing to innovate and address patient needs effectively, affirming its role as a key player in the biopharmaceutical industry.

Through strategic collaborations and a robust research and development framework, SK Biopharmaceuticals appears poised to navigate the complexities of drug development and commercialization successfully, steering forward with a commitment to enhancing patient care in neuroscience.